The effectiveness and cost effectiveness of COenzyme Q10 in heaRt fAiLure with reduced ejection fraction (CORAL): a pragmatic, patient-centred, data-enabled trial in primary care

Start Date01 Oct 2024

Sponsor / Collaborator

University of Bristol

NCT06452134 / Not yet recruitingPhase 4IIT

Evaluation the Effect of Coenzyme Q10 on Tissue Healing Process in Patients Undergoing Wisdom Tooth Extraction in the City of Sanandaj-Iran in 1402: a Double-blinded Clinical Trial Study

The goal of this clinical trial is to asses the effect of Coenzyme Q10 administration in patients from any gender group who are older than 18 years old undergoing wisdom tooth extraction. The main questions it aims to answer are:
does Coenzyme Q10 help with better tissue healing? does Coenzyme Q10 administration lower the prevalence of Dry socket after surgery? does Coenzyme Q10 prevent TMD (Temporomandibular disorders) while recovering from surgery? how does Coenzyme Q10 administration effect the answers to SF-36 health survey in patients? Researchers will compare Coenzyme Q10 to a placebo (a look-alike substance that contains no drug) to see if it has any effect on mentioned parameters.
Participants will:
take coenzyme Q10 (100mg) daily for 30 days after surgery.
will be examined and evaluated 1, 7, 14 and 30 days after completion of surgery.

Start Date01 Jul 2024

Sponsor / Collaborator-

100 Clinical Results associated with Ubidecarenone

100 Translational Medicine associated with Ubidecarenone

100 Patents (Medical) associated with Ubidecarenone

4,618

Literatures (Medical) associated with Ubidecarenone

01 Jun 2024·Toxicology reports

Reciprocal crosslink among MeCP2/BDNF /CREB signaling pinpointed in autism spectrum disorder

Article

Author: Elhefnawei, Doaa M ; Kadry, Mai O ; El-Desouky, Mohamed A ; Mahmoud, Ahlam H

Autism spectrum disorder, or individual disability (ID), is a condition characterized by complications in social interaction, restricted repetitive behavior, and difficulties in social communication. Neuquinon (NQ) possess a powerful therapeutic potential in various neurodegenerative disease. Nevertheless, contributing to NQ's low water solubility and bioavailability, its medicinal use has been constrained. Liposomes were supposed to be prospective drug-delivering agents for NQ, crossing the blood-brain barrier (BBB), and reaching the target organs. The current investigation aims to track the signaling pathways that govern NQ and liposomal neuquinon (LNQ) action in autistic models generated by ethyl formic acid. The neurotransmitters gamma amino-butyric acid (GABA), acetylcholine (ACh), and acetylcholinesterase (AChE) in addition to, the gene expressions of brain-derived neurotrophic factor (BDNF), cAMP response element-binding protein (CREB), and methyl-CpG-binding protein 2 (MeCP2) and the DNA damage COMET analysis at different time intervals of the study, were assessed. EFA in a dose of 500 mg/kg BW was used to induce autism in rats, and then NQ and LNQ were administered in 10 mg/kg and 2 mg/kg BW, respectively. The results revealed that NQ and LNQ significantly down-regulated BDNF, GABA, and AChE; on the other hand, they up-regulated MeCP2, CREB gene expressions, and ACh action. NQ and LNQ displayed improvement in DNA damage in almost all brain regions after EFA alterations; even better results were noticed post-LNQ therapy. Therefore, it may be concluded that neuquinon and liposomal-loaded neuquinon have a therapeutic index versus EFA-induced autism in a rat model.

01 Apr 2024·Current medicinal chemistry

Coenzyme Q₁₀ for Enhancing Physical Activity and Extending the Human Life Cycle

Review

Author: Indika, Neluwa-Liyanage Ruwan ; Hrynovets, Ihor ; Gasmi, Amin ; Lysiuk, Roman ; Bjørklund, Geir ; Yeromina, Hanna ; Lenchyk, Larysa ; Peana, Massimiliano ; Uryr, Taras ; Semenova, Yuliya

Background::

Coenzyme Q (CoQ) is an enzyme family that plays a crucial role in maintaining the electron transport chain and antioxidant defense. CoQ10 is the most common form of CoQ in humans. A deficiency of CoQ10 occurs naturally with aging and may contribute to the development or progression of many diseases. Besides, certain drugs, in particular, statins and bisphosphonates, interfere with the enzymes responsible for CoQ10 biosynthesis and, thus, lead to CoQ10 deficiency.

Objectives::

This article aims to evaluate the cumulative studies and insights on the topic of CoQ10 functions in human health, focusing on a potential role in maintaining physical activity and extending the life cycle.

Results::

Although supplementation with CoQ10 offers many benefits to patients with cardiovascular disease, it appears to add little value to patients suffering from statin-associated muscular symptoms. This may be attributed to substantial heterogeneity in doses and treatment regimens used.

Conclusion::

Therefore, there is a need for further studies involving a greater number of patients to clarify the benefits of adjuvant therapy with CoQ10 in a range of health conditions and diseases.

01 Mar 2024·Neural regeneration research

Single-neuron neurodegeneration as a degenerative model for Parkinson's disease.

Review

Author: Huenchuguala, Sandro ; Segura-Aguilar, Juan

The positive effect of levodopa in the treatment of Parkinson's disease, although it is limited in time and has severe side effects, has encouraged the scientific community to look for new drugs that can stop the neurodegenerative process or even regenerate the neuromelanin-containing dopaminergic nigrostriatal neurons. Successful preclinical studies with coenzyme Q10, mitoquinone, isradipine, nilotinib, TCH346, neurturin, zonisamide, deferiprone, prasinezumab, and cinpanemab prompted clinical trials. However, these failed and after more than 50 years levodopa continues to be the key drug in the treatment of the disease, despite its severe side effects after 4-6 years of chronic treatment. The lack of translated successful results obtained in preclinical investigations based on the use of neurotoxins that do not exist in the human body as new drugs for Parkinson's disease treatment is a big problem. In our opinion, the cause of these failures lies in the experimental animal models involving neurotoxins that do not exist in the human body, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine, that induce a very fast, massive and expansive neurodegenerative process, which contrasts with the extremely slow one of neuromelanin-containing dopaminergic neurons. The exceedingly slow progress of the neurodegenerative process of the nigrostriatal neurons in idiopathic Parkinson's patients is due to (i) a degenerative model in which the neurotoxic effect of an endogenous neurotoxin affects a single neuron, (ii) a neurotoxic event that is not expansive and (iii) the fact that the neurotoxin that triggers the neurodegenerative process is produced inside the neuromelanin-containing dopaminergic neurons. The endogenous neurotoxin that fits this degenerative model involving one single neuron at a time is aminochrome, since it (i) is generated within neuromelanin-containing dopaminergic neurons, (ii) does not cause an expansive neurotoxic effect and (iii) triggers all the mechanisms involved in the neurodegenerative process of the nigrostriatal neurons in idiopathic Parkinson's disease. In conclusion, based on the hypothesis that the neurodegenerative process of idiopathic Parkinson's disease corresponds to a single-neuron neurodegeneration model, we must search for molecules that increase the expression of the neuroprotective enzymes DT-diaphorase and glutathione transferase M2-2. It has been observed that the activation of the Kelch-like ECH-associated protein 1/nuclear factor (erythroid-derived 2)-like 2 pathway is associated with the transcriptional activation of the DT-diaphorase and glutathione transferase genes.

News (Medical) associated with Ubidecarenone

30 May 2024

·www.prnewswire.com

New Study Shows Petadolex Butterbur may be an Effective Supplement for Migraine Management

TAMPA, Fla., May 30, 2024 /PRNewswire/ -- A new review in the journal Practical Neurology highlights the efficacy of the supplement Petadolex in preventing migraines. The comprehensive review of "Nutraceuticals for Migraine Management" conducted by headache specialists Drs L. Denysenko and D. Kuruvilla details the effectiveness of four widely available supplements commonly used for migraine prevention. Only Petadolex has data to support reducing migraine frequency with "a predictable dose-response relationship." Continue Reading Only Petadolex has data to support reducing migraine frequency with "a predictable dose-response relationship." Post this Petadolex Butterbur Supplement Proven Effective for Migraine Management Petadolex, a patented preparation of the European butterbur plant, was compared to Coenzyme Q10 (CoQ10), Vitamin D, and Curcumin. Petadolex stands out with numerous clinical trials demonstrating its safety and efficacy as well as laboratory studies showing how and why it works. While Petadolex is derived from butterbur, unlike other available or generic butterbur supplements, it is a proprietary liquid extract of the plant which ensures that potentially toxic native butterbur chemicals are eliminated. The resulting supplement, Petadolex, has reliable, safe and effective pharmacology and contains a minimum 15% petasins and isopetasins, the essential active ingredients proven effective in patient studies. Petadolex, the only liquid form of butterbur used in clinical trials, has been shown to work by multiple mechanisms including inhibiting the release of calcitonin gene-related peptide (CGRP). CGRP, the brain chemical which plays a key role in causing migraine symptoms, is blocked or inhibited by the newest category of migraine prevention prescription drugs. Modifying CGRP is also a natural mechanism of Petadolex as well as blocking migraines by acting on select calcium channel pathways to desensitize sensory neurons. Dr. Lex Denysenko, the lead author of the review, notes: "Our review highlights the potential of butterbur liquid extract, particularly Petadolex, in migraine management. The evidence suggests butterbur may offer a valuable therapy for reducing migraine frequency and improving patient outcomes." For clinicians and individuals seeking natural alternatives to prescription drugs, Petadolex holds promise as a natural remedy for migraine prevention. To learn more about Petadolex and the benefits of its butterbur extract, visit . References About Petadolex Petadolex® butterbur supplement, manufactured by Linpharma, provides premium quality and efficacy for your health needs. Produced in Germany, where supplements are held to the same rigorous standards as medications, our products meet stringent safety and ingredient-purity benchmarks surpassing U.S. standards and domestically manufactured supplements. Backed by Weber & Weber, a renowned German OTC company with over 60 years of expertise in pharmaceuticals, herbal extracts, homeopathic products, and dietary supplements, Linpharma proudly represents these exceptional products in the USA and Canada. Learn more at SOURCE Linpharma

05 Apr 2024

·www.biospace.com

BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform

Insightful data comes from collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and leading hospitals in Mexico across various stages of development BOSTON--(BUSINESS WIRE)-- BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico. The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif. This press release features multimedia. View the full release here: A graphical representation of BPGbio's NAi Interrogative Biology Platform (Graphic: Business Wire) Highlights from posters include: New data further validating the mitochondrial-centric effect of BPM31510 on the immune system. In addition to its direct cell-killing effect on tumor cells, data supports the potential use of BPM31510 in the intersection of tumor immunology and tumor metabolism BPGbio’s NAi Platform coupled with a subsequent deep learning algorithm implemented on BRG399, a novel pan-cancer drug candidate, can improve efficiency in drug development by rapidly predicting anti-cancer efficacy in silico before conducting resource intensive preclinical experiments A new study in Mexico further validating the utility of BPGbio’s prostate cancer biomarker, the pstateDx™ test, which was discovered by the NAi Platform, in an independent population New data validating UBE2M, a novel potential therapeutic target for cancer, identified by the NAi Platform. “Our company has pioneered and proliferated a unique biology-first approach to the use of AI in drug discovery and development as we focus on high unmet disease indications,” said Niven R. Narain, Ph.D., President and CEO, BPGbio, Inc. “Our NAi Interrogative Biology platform has guided our development team via many successful research collaborations enabling us to deliver positive clinical trial readouts across multiple indications in various stages of development. Our goal is to offer potential and hope to patients and families facing ravaging diseases like GBM and pancreatic cancer.” Presentation Details: Abstract 3527: Application of deep learning-based drug sensitivity prediction model on a novel anticancer drug Presentation: Monday, April 8, 2024, 1:30-5:00 p.m. in Poster Section 35 Abstract 3751: Diagnostic assessment of Filamin A (FLNA) as a serum biomarker for identification of benign prostatic hyperplasia vs. aggressive prostate cancer in a prospective Mexican cohort Presentation: Monday, April 8, 2024, 1:30 - 5:00 p.m. in Poster Section 44 Abstract 4694: In charge: Targeting neddylation of UBE2M for anticancer therapy Presentation: Tuesday, April 9, 2024, 9:00 a.m. - 12:30 p.m. in Poster Section 28 Abstract 6518: BPM31510: Targeting the tumor microenvironment (TME) via mitochondrial-mediated ROS production Presentation: Tuesday, April 9, 2024, 1:30 - 5:00 p.m. in Poster Section 47 About the NAi Interrogative Biology Platform The NAi Interrogative Biology Platform combines BPGbio’s industry-leading, clinically annotated proprietary biobank, purpose-built Bayesian artificial intelligence, and the compute power of the world’s fastest supercomputer, Frontier, housed at Oak Ridge National Laboratory. Collectively, these tools enable the company to bring artificial intelligence to biology inspiring AI-driven target nomination, discovery, molecule design, and more. The platform has been used to identify more than 100 drug targets and diagnostic biomarkers and supported research collaborations with a range of government, industry and academic partners including the U.S. Department of Defense, Sanofi, and Harvard Medical School. About BPM31510 BPM31510 is BPGbio’s lead candidate in late-stage development for glioblastoma multiforme (GBM) and pancreatic cancer. The compound has demonstrated a tolerable safety pro shown potential clinical benefit in both populations. The mechanism of action of BPM31510 was first validated by data from BPGbio’s NAi Interrogative Biology platform, which suggested that there is a hallmark shift in the tumor microenvironment (TME) induced by BPM31510 which modulates mitochondrial oxidative phosphorylation in highly aggressive tumors. About BRG399 BRG399, a BPGbio-developed oral experimental drug with favorable pharmacological properties for clinical testing, is a first in class anti-mitotic agent with broad-spectrum anti-cancer activity. BRG399 is being studied for its therapeutic potential as a treatment for solid and liquid tumor cancers as well as diseases associated with inflammation. BPGbio’s scientists reported that the anti-mitotic activity of BRG399 is the result of an inhibition of microtubule polymerization. About pstateDx™ BPGbio’s pstateDx™ test is the first diagnostic product discovered by the company’s AI-powered NAi Interrogative Biology platform to be commercially launched. The pstateDx™ test is a non-PSA based, unique molecular diagnostic blood test that measures filamin A, a key biological driver of prostate cancer. The test provides a risk score to help clinicians differentiate between BPH and aggressive prostate cancer at the time of initial screening. It may help reduce unnecessary biopsies in the BPH population, where men are sometimes repeatedly biopsied even though they do not have prostate cancer. About BPGbio, Inc. BPGbio is a leading AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology, and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way we understand aging, human performance, and diagnose and treat disease. For more information, visit bpgbio.com

Clinical StudyAACR

06 Mar 2024

·www.prnewswire.com

Puritan's Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands

NEW YORK, March 6, 2024 /PRNewswire/ -- As global health awareness has increased, there has been a notable shift in people's focus from "treatment" to "prevention" of diseases. On December 4, 2023, the International Self-Care Foundation and the Dietary Guidance Committee of the Chinese Aging Well Association (CAWA) jointly organized the 2023 China Nutrition and Health Industry High-Quality Development Conference. Renowned Chinese experts delivered thematic speeches and participated in panel discussions on nutrition and health issues. Throughout the conference, experts analyzed the current state of cardiovascular research and made predictions for the future of cardiovascular disease. Puritan's Pride™, a global brand, was honored with the Cardiovascular Health Outstanding Contribution Award during the event. In addition, its Coenzyme Q10 product line was recognized with the 2023 Dietary Guidance Committee of CAWA Recommended Product Award. Continue Reading Puritan’s Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands Puritan's Pride™ prioritizes providing high-quality nutritional diet services to all families. With a strong emphasis on health and nutrition, the company uses advanced scientific research and patented technologies to create products from high-quality, safe natural ingredients. It has established itself as one of the leading nutritional supplement brands, boasting a customer base of more than six million satisfied individuals. Puritan's Pride™ is the preferred choice for people seeking health supplements, excelling in both quality and affordability. Puritan's Pride™ is a leading health supplement company established in 1973 in Long Island, New York. It boasts a rich history spanning 51 years. As one of the largest and most comprehensive health supplement companies in the United States, it specializes in the development, production, and sale of vitamins, minerals, herbs, and other health, beauty, and weight loss products, offering a range of more than 1200 nutritional products. With Coenzyme Q10, Lutein, and Lycopene as its star products, all products are certified by the U.S. FDA. Puritan's Pride has expanded its product reach to more than 90 countries and regions globally, with a monthly production capacity of up to 2.15 billion pills since its establishment. SOURCE Puritan's Pride

100 Deals associated with Ubidecarenone

External Link

KEGG	Wiki	ATC	Drug Bank
D01065	Ubidecarenone	C01EB09	DB09270

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	JP	Eisai Co., Ltd.	27 Jul 1976

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma Multiforme	Phase 2	US	Berg LLC	22 Aug 2022
Advanced Pancreatic Adenocarcinoma	Phase 2	US	Berg LLC	06 Jul 2016
Advanced Pancreatic Adenocarcinoma	Phase 2	GB	Berg LLC	06 Jul 2016
Squamous Cell Carcinoma	Phase 2	US	Berg LLC	01 Jun 2008
Coenzyme Q10 Deficiency	Phase 2	US	BPGbio Inc	-
Glioblastoma	Phase 2	US	BPGbio Inc	-
Pancreatic Cancer	Phase 2	US	BPGbio Inc	-
Epidermolysis Bullosa	Phase 1	US	Berg LLC	10 Aug 2016
FGF19 positive Solid Tumors	Phase 1	US	Berg LLC	01 Oct 2013
Neoplasm Metastasis	Phase 1	US	Berg LLC	01 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02650804 (Biospace) Manual	Phase 2	Pancreatic Cancer Second line \| Third line	19	BPM31510+gemcitabine	dwbisbjsjg(ewvstvjftw) = ycqupltvum meogkdclpq (fzympborjo )	Positive	18 Jan 2024
				Gemcitabine	dwbisbjsjg(ewvstvjftw) = bhshdhthat meogkdclpq (fzympborjo )
EASD2023	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	52	Coenzyme Q10 240mg	plidrxlwtu(hzyovbszyv) = htryaptbbw bltwhkvcpv (ebamehttrw ) View more	Positive	05 Oct 2023
				coenzyme Q10	plidrxlwtu(hzyovbszyv) = bbucnqpeek bltwhkvcpv (ebamehttrw ) View more
ARVO2023	Not Applicable	-	-	coenzyme Q10	pqyibiabsr(mxautkuawh) = rixjrqznyz tcwoyirfii (spyivskcot ) View more	-	23 Apr 2023
				H2O2+CoQ10	pqyibiabsr(mxautkuawh) = rmwiwfotln tcwoyirfii (spyivskcot ) View more
NCT02865460 (CTgov)	Phase 3	Fatigue Syndrome, Chronic \| Persian Gulf Syndrome \| Coenzyme Q10 Deficiency	100	Ubiquinol (Ubiquinol)	wmsvontmlo(clkwogqrjf) = apqbnrkjob ndnjjygqud (pprqkfjkav, mggjtgqysm - sauxecxhfu) View more	-	15 Feb 2023
				Placebo (Placebo)	wmsvontmlo(clkwogqrjf) = xnqfdrplyi ndnjjygqud (pprqkfjkav, dxvrsdvcrp - pkexirmgkc) View more
EUCTR2020-005961-16-DK \| NCT04960215 (Pubmed)	Phase 2	Post Acute COVID 19 Syndrome	121	Coenzyme Q10 500 mg/day	tdzqajwjfi(gtubwisyye): mean difference = 0.01 (95% CI, -0.02 to 0.04), P-Value = 0.45 View more	Negative	02 Nov 2022
				coenzyme Q10 (Placebo)
NCT03133793 (CTgov)	Phase 2	Heart Failure, Diastolic	216	Placebo powder (Placebo Only)	iuihqcgibi(xgufuxqtya) = irwaqjancm jjyhlsluvq (ivcbwvujfw, peuugqhgov - xynwkgtkql) View more	-	03 Mar 2022
				Placebo powder+CoQ10 (CoQ10 Only)	iuihqcgibi(xgufuxqtya) = qhrzeqxbhc jjyhlsluvq (ivcbwvujfw, fmabrtcnef - vceqlgflri) View more
NCT02934555 (CTgov)	Phase 2	Post-Cardiac Arrest Syndrome \| Heart Arrest	48	Ensure+Ubiquinol	gsmzsjjfpi(itulglzyzg) = themtvraws ssihcpqskh (dexfcqouda, yrjjraxibu - bzoumztzzu) View more	-	15 Feb 2021
ESMO2020	Phase 2	Advanced Pancreatic Ductal Adenocarcinoma	35	BPM 31510-IV + gemcitabine	ckgitnocey(fennqsgfmu) = qmjtvhuosk ltwhzkeguu (vkoztbrlfn ) View more	-	17 Sep 2020
ARVO2019	Not Applicable	-	-	Coenzyme Q10	zgttpmperv(zspbfvsvth) = reduced 29% in treated cells xaaltdxvyu (hsdqvrpmkv ) View more	-	01 Jul 2019
NCT00652080 (CTgov)	Phase 1/2	Squamous Cell Carcinoma	35	Cream+API 31510 (Safety Population)	kigvvjbqhr(dtybbmuysp) = mtpauonfvh cdqwvcncki (gzrbkkcnsf, lihkytnkry - rsxmyicxlj) View more	-	15 Feb 2019
				Cream+API 31510 (ITT Population)	xevwwuzdts(fjtdtcuuhz) = pfgvplsptb nedmkcsygp (vizbnaigsb, svmtvovokc - uaeaydorlh)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis